Tonix Pharmaceuticals Holding Corp. (TNXP): Total Liabilities
$32.02M
As of 2025-12-31
$31.81M
As of 2026-06-30
+20.0%
3-year compound annual growth
+24.9%
5-year compound annual growth
+16.8%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $32.02M | +37.2% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $23.33M | -52.3% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $48.93M | +164.4% | 2025-03-18, Balance as of period end |
| 2022-12-31 | $18.51M | -16.6% | 2024-04-01, Balance as of period end |
| 2021-12-31 | $22.18M | +110.6% | 2023-03-13, Balance as of period end |
| 2020-12-31 | $10.54M | +104.9% | 2022-03-14, Balance as of period end |
| 2019-12-31 | $5.14M | +93.6% | 2021-03-15, Balance as of period end |
| 2018-12-31 | $2.65M | +24.2% | 2020-03-24, Balance as of period end |
| 2017-12-31 | $2.14M | -0.5% | 2019-03-18, Balance as of period end |
| 2016-12-31 | $2.15M | -68.2% | 2018-03-09, Balance as of period end |
| 2015-12-31 | $6.76M | +95.8% | 2017-04-13, Balance as of period end |
| 2014-12-31 | $3.45M | +55.1% | 2016-03-03, Balance as of period end |
| 2013-12-31 | $2.22M | +92.1% | 2015-02-27, Balance as of period end |
| 2012-12-31 | $1.16M | -59.8% | 2014-03-28, Balance as of period end |
| 2011-12-31 | $2.88M | +701.0% | 2013-11-22, Balance as of period end |
| 2010-12-31 | $359.5K | n/a | 2012-03-30, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $32.02M | +37.2% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $19.38M | -32.0% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $5.49M | -10.4% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $85.04M | +6.2% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $38.11M | +4.6% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $18.04M | -47.5% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $72.68M | +65.0% |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | $34.90M | +208.9% |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $57.01M | +28.3% |
Compare TNXP, EVMN, CVSI, EMMA side by side · Screen every company in Pharmaceutical Preparations ↗